SK Biopharmaceuticals Co. Ltd. and Eurofarma Laboratórios SA launched a new joint venture called Mentis Care Inc. Oct. 21, dedicated to developing an AI-powered platform for epilepsy management.
Biopharma companies announced $73.38 billion in deals from 240 transactions during the third quarter (Q3) of 2025, bringing the year-to-date total to $212.44 billion, up from $149.87 billion in the same period of 2024. The total marks the highest deal value through Q3 ever recorded by BioWorld.
Neuphoria Therapeutics Inc.’s phase III study of social anxiety disorder has missed its primary and secondary endpoints, prompting the company to stop the program’s development and hold a full strategic review of its operations and portfolio. It’s the second stumble for lead candidate BNC-210, a negative allosteric modulator of alpha7 nicotinic acetylcholine receptor, in the indication.
H. Lundbeck A/S and Contera Pharma A/S have entered into a strategic research collaboration designed to accelerate the discovery and development of innovative oligonucleotide-based medicines for serious neurological conditions with unmet needs.
Restrictive element-1 silencing transcription factor (REST) has key roles in neuronal differentiation, structural remodeling and plasticity, contributing to neuronal homeostasis in postnatal neurons. It acts as a suppressor of neuronal gene expression in stem and progenitor cells, and abnormal accumulation of it has been linked to several neurological disorders, like Huntington’s disease, epilepsy and stroke.
Do men’s and women’s brains age equally? Women are more often diagnosed with Alzheimer’s disease (AD) than men. Age is the primary known risk factor for AD prevalence, and both aging and AD are associated with brain atrophy, but it is still not clear whether men and women differ regarding brain decline in aging. There is mixed evidence regarding this topic, since most of the larger studies have shown an abrupt decay of total gray matter and hippocampal volume in men, but other studies have found steeper total gray matter decline in women.
Comind Technologies Ltd. secured $60 million in funding for its optical neuromonitoring device which non-invasively measures key physiological parameters of the brain to provide critical information on its health. The technology could significantly improve the way the brain is monitored by addressing key challenges of current methods such as inaccuracy, invasiveness and limited availability when needed.
Inhibiting human monoamine oxidase (MAO)-B to increase the availability of monoamine neurotransmitters is a clinically approved strategy for treating Parkinson’s disease, yet available inhibitors lack efficacy or increase risk of adverse events. Researchers at Hefei University of Technology and collaborators started from the clinically improved MAO-B inhibitor safinamide and generated various derivatives, among which [I] and [II] emerged as the most promising.
Boston Scientific Corp. moved to acquire the balance of Nalu Medical Inc. in a $533 million cash deal, expanding its chronic pain portfolio with the addition of peripheral nerve stimulation. The Nalu neurostimulation system delivers mild electrical impulses to interrupt aberrant pain signals from nerves in the shoulder, knee and lower back before they reach the brain.
RSS
